Arizona Sen. Martha McSally is introducing a drug pricing bill this week that would allow Medicare to directly negotiate the prices of medicines “that are past their original patent expiration but still maintain a monopoly for that drug.”
McSally’s move is notable as Republicans have traditionally opposed allowing government intervention in drug price negotiations. Only two House Republicans voted for House Democrats’ signature government drug price negotiation bill, H.R. 3 (116), which cleared the lower chamber late last year.
But proponents of government negotiations shouldn’t get too excited just yet. Definitions of “original patent” and “monopoly” will be key to a better understanding of which drugs would be affected by McSally’s plan. Experts see a number of ways in which her plan looks to be weaker than House Democrats plan.
While H.R. 3 permits negotiation on drugs that lack biosimilar or generic competition regardless of whether they are protected by patents or FDA-granted marketing exclusivity, the time at which drug companies have the most leverage to keep prices high, McSally’s plan would have the government intervene at a later point.
Full Content: The Hills
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI